Whereas PD-1 is recognized as a brake on T cells, drugs that target PD-1 and PD-L1 have demonstrated promising therapeutic effects in some highly immunogenic tumours, such as non-Hodgkin lymphoma, non-small cell lung cancer (NSCLC), and melanoma. Here, CD274 is linked to non-small cell lung carcinoma.